After seven months of clinical investigation, Validcare, a research software and services
company, announced March 22 that its team of principal investigators met with
members of the U.S. Food and Drug Administration’s Cannabis Product Council
(formerly known as the Cannabis Work Group) to share initial findings from the
industry-sponsored, decentralized human safety study of hemp-derived CBD products.
Preliminary findings showed no evidence of liver disease and no increase in the
prevalence of elevated liver function tests in adults who ingest oral CBD products when
compared to a population with a similar incidence of medical conditions.